GENE ONLINE|News &
Opinion
Blog

2020-10-24| Asia-PacificCOVID-19

Taiwanese Government Grants 16 Million to aid Adimmune’s COVID-19 Vaccine Trials

by Tyler Chen
Share To

By Tyler Chen

As the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia and the only PIC/S GMP manufacturer of human vaccines in Taiwan, Taiwan’s biotech company Adimmune Corporation lately acquired 458 million TWD (around 16 million USD) grant from the government to advance COVID-19 vaccine clinical trials.

 

AdimrSC-2f Under Phase 1 Trial

Adimmune’s self-developed vaccine AdimrSC-2f (SARS-COV-2) has entered Phase 1 clinical trial on August 24, and Phase 2 is expected to begin in November.

The study (NCT04522089) aims to investigate the safety and immunogenicity of AdimrSC-2f. Phase 1 of the trial includes 68 healthy subjects aged 20 to 60-year-old and breaking into 4 separate groups. Four groups will respectively be given a low, medium, high dose of AdimrSC-2f, while one group will receive a low dose of AdimrSC-2f with aluminum as an adjuvant. The trial is conducted under a randomized, single-centered setting at National Taiwan University Hospital.

If the result shows any promise, AdimrSC-2f will enter Phase 2 on November 20, enrolling at least 1,500 subjects cooperating with more hospitals. The overall study is estimated to complete on March 20, 2021.

To strengthen the manufacturing power, Adimmune, on June 9, announced the 700 million TWD investment (around 24 million USD) to expand a new production line to meet the surging needs for vaccines. The expansion is expected to complete in 2021.

Adimmune’s Partnership

Founded in 1965, Adimmune has worked with one of Japan’s largest vaccine researchers and manufacturers, Kitasato Daiichi Sankyo, obtaining the technology for tetanus vaccines, Japanese encephalitis vaccines, influenza vaccines, bird flu vaccines’ production. Moreover, Adimmune joined forces with Crucell N.V., which Johnson & Johnson acquired to establish Adimmune’s EU PIC/S GMP quality system.

Adimmune’s product line includes the Trivalent Influenza vaccine, the Tetravalent Influenza vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, Japanese Encephalitis Vaccine (JEV), and Tetanus toxoid, and purified Tuberculin.

Related Article: Taiwan’s TTY Biopharm Company Signs COVID-19 Vaccine Deal with BioNTech for 30 Million Doses

References
  1. http://www1.cde.org.tw/ct_taiwan/search_case2.php?caseno%5B4%5D=6258
  2. http://www.adimmune.com.tw/news_content.php?id=229
  3. https://clinicaltrials.gov/ct2/show/NCT04522089

 

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Taiwanese Hospitals Make Strong Showing in “World’s Best Hospitals” Ranking
2024-03-12
Saudi Arabia Reveals Grand Ambition to Become a Global Biotech Powerhouse by 2040
2024-01-26
LATEST
Preventive Medicine for Neurodegeneration on the Rise: New Breakthrough in Routine Blood Testing for Alzheimer’s Disease
2024-05-20
Discrimination Leads to Rapid Aging, Science Shows the Detrimental Effects of this Act
2024-05-17
A New Study has Linked Treatment Resistant Depression to Body Mass Index
2024-05-16
AI Reveals Sex-Related Brain Differences and Precision Medicine Potential
2024-05-16
The EU Sustainability Directive’s Influence on Pharmaceutical Supply Chains
2024-05-15
New UC Berkeley Study Challenges Traditional Views on Lactate and Carbohydrate Metabolism
2024-05-15
First Person to Receive Transplanted Pig Kidney has Died
2024-05-13
EVENT
Scroll to Top